<!DOCTYPE html>
<html lang="en">
    <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
        <title>52</title>

        <link href="bootstrap.min.css" rel="stylesheet">
        <link href="custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="treatments.css" rel="stylesheet" type="text/css"/>
        <link href="recreated_tables.css" rel="stylesheet" type="text/css"/>
           <style>
        .sep {
            border-bottom:1px solid lightgray;
        }
        .sep td {
            padding-bottom:5px;
            padding-top:5px;
        }
        br {
            display: block;
            margin-top: 5px 0;
        }
    </style>
    </head>
    <body>
            <br />
            <div class="container">
                <ol class="breadcrumb small">
                
                        <li class="active">Trichomoniasis</li>
                </ol>
              </div><!-- end of breadcrumbs -->
            
        <div class="container"><h4>Diagnostic Considerations</h4>
<p>The use of highly sensitive and specific tests is recommended for detecting <em>T. vaginalis</em>. Among women, NAAT is highly sensitive, often detecting three to five times more <em>T. vaginalis</em> infections than wet-mount microscopy, a method with poor sensitivity (51%–65%) <sup id="fnref:663"><a class="footnote-ref" href="#fn:663" rel="footnote">1</a></sup>  <sup id="fnref:664"><a class="footnote-ref" href="#fn:664" rel="footnote">2</a></sup>. The APTIMA <em>T. vaginalis</em> assay (Hologic Gen-Probe, San Diego, CA) is FDA-cleared for detection of <em>T. vaginalis</em> from vaginal, endocervical, or urine specimens from women. This assay detects RNA by transcription-mediated amplification with a clinical sensitivity of 95.3%–100% and specificity of 95.2%–100% <sup id="fnref:665"><a class="footnote-ref" href="#fn:665" rel="footnote">3</a></sup>  <sup id="fnref:666"><a class="footnote-ref" href="#fn:666" rel="footnote">4</a></sup>. Among women, vaginal swab and urine have up to 100% concordance <sup id="fnref:663"><a class="footnote-ref" href="#fn:663" rel="footnote">1</a></sup>. As analyte-specific reagents, this assay can be used with urine or urethral swabs from men if validated per CLIA regulations. The sale, distribution, and use of analyte-specific reagents are allowed under 21 C.F.R. 809.30 pertaining to in vitro diagnostic products for human use. For <em>T. vaginalis</em> diagnosis in men, the sensitivity of self-collected penile-meatal swabs was higher than that of urine in one study (80% and 39%, respectively) <sup id="fnref:667"><a class="footnote-ref" href="#fn:667" rel="footnote">5</a></sup>. The BD Probe Tec TV Qx Amplified DNA Assay (Becton Dickinson, Franklin Lakes, New Jersey) is FDA-cleared for detection of <em>T. vaginalis</em> from endocervical, vaginal, or urine specimens from women. Although it might be feasible to perform these tests on the same specimen used for chlamydia and gonorrhea screening, the epidemiology of trichomoniasis is distinct and should not be overlooked in older adults.</p>
<p>Other FDA-cleared tests to detect <em>T. vaginalis</em> in vaginal secretions include the OSOM Trichomonas Rapid Test (Sekisui Diagnostics, Framingham, MA), an antigen-detection test using immunochromatographic capillary flow dipstick technology that can be performed at the point of care, and the Affirm VP III (Becton Dickinson, Sparks, MD), a DNA hybridization probe test that evaluates for <em>T. vaginalis</em>, <em>G. vaginalis</em>, and <em>Candida albicans</em>. The results of the OSOM Trichomonas Rapid Test are available in approximately 10 minutes, with sensitivity 82%–95% and specificity 97%–100% <sup id="fnref:666"><a class="footnote-ref" href="#fn:666" rel="footnote">4</a></sup>  <sup id="fnref:668"><a class="footnote-ref" href="#fn:668" rel="footnote">6</a></sup>. Self-testing might become an option, as a study of 209 young women aged 14–22 years found that &gt;99% could correctly perform and interpret her own self-test using the OSOM assay, with a high correlation with clinician interpretation (96% agreement, κ = 0.87) <sup id="fnref:669"><a class="footnote-ref" href="#fn:669" rel="footnote">7</a></sup>. The results of the Affirm VP III are available within 45 minutes. Sensitivity and specificity are 63% and 99.9%, respectively, compared with culture and TMA; sensitivity might be higher among women who are symptomatic <sup id="fnref:670"><a class="footnote-ref" href="#fn:670" rel="footnote">8</a></sup>  <sup id="fnref:671"><a class="footnote-ref" href="#fn:671" rel="footnote">9</a></sup>. Neither the OSOM nor the Affirm VP III test is FDA-cleared for use with specimens obtained from men.</p>
<p>Culture was considered the gold standard method for diagnosing <em>T. vaginalis</em> infection before molecular detection methods became available. Culture has a sensitivity of 75%–96% and a specificity of up to 100% <sup id="fnref:475"><a class="footnote-ref" href="#fn:475" rel="footnote">10</a></sup>. In women, vaginal secretions are the preferred specimen type for culture, as urine culture is less sensitive <sup id="fnref:475"><a class="footnote-ref" href="#fn:475" rel="footnote">10</a></sup>  <sup id="fnref:672"><a class="footnote-ref" href="#fn:672" rel="footnote">11</a></sup>  <sup id="fnref:673"><a class="footnote-ref" href="#fn:673" rel="footnote">12</a></sup>. In men, culture specimens require a urethral swab, urine sediment, and/or semen. To improve yield, multiple specimens from men can be used to inoculate a single culture.</p>
<p>The most common method for <em>T. vaginalis</em> diagnosis might be microscopic evaluation of wet preparations of genital secretions because of convenience and relatively low cost. Unfortunately, the sensitivity of wet mount is low (51%–65%) in vaginal specimens <sup id="fnref:475"><a class="footnote-ref" href="#fn:475" rel="footnote">10</a></sup>  <sup id="fnref:666"><a class="footnote-ref" href="#fn:666" rel="footnote">4</a></sup> and lower in specimens from men (e.g., urethral specimens, urine sediment, and semen). Clinicians using wet mounts should attempt to evaluate slides immediately because sensitivity declines as evaluation is delayed, decreasing by up to 20% within 1 hour after collection <sup id="fnref:674"><a class="footnote-ref" href="#fn:674" rel="footnote">13</a></sup>  <sup id="fnref:675"><a class="footnote-ref" href="#fn:675" rel="footnote">14</a></sup>. When highly sensitive (e.g., NAAT) testing on specimens is not feasible, a testing algorithm (e.g., wet mount first, followed by NAAT if negative) can improve diagnostic sensitivity in persons with an initial negative result by wet mount <sup id="fnref:475"><a class="footnote-ref" href="#fn:475" rel="footnote">10</a></sup>. Although <em>T. vaginalis</em> may be an incidental finding on a Pap test, neither conventional nor liquid-based Pap tests are considered diagnostic tests for trichomoniasis, because false negatives and false positives can occur. </p>
<h4>Treatment</h4>
<p>Treatment reduces symptoms and signs of <em>T. vaginalis</em> infection and might reduce transmission. Likelihood of adverse outcomes in women with HIV also is reduced with <em>T. vaginalis</em> therapy.</p>
<p>Alcohol consumption should be avoided during treatment with nitroimidazoles. To reduce the possibility of a disulfiram-like reaction, abstinence from alcohol use should continue for 24 hours after completion of metronidazole or 72 hours after completion of tinidazole.</p>
<p>The nitroimidazoles are the only class of antimicrobial medications known to be effective against <em>T. vaginalis</em> infections. Of these drugs, metronidazole and tinidazole have been cleared by FDA for the oral or parenteral treatment of trichomoniasis. Tinidazole is generally more expensive, reaches higher levels in serum and the genitourinary tract, has a longer half-life than metronidazole (12.5 hours versus 7.3 hours), and has fewer gastrointestinal side effects <sup id="fnref:676"><a class="footnote-ref" href="#fn:676" rel="footnote">15</a></sup>  <sup id="fnref:677"><a class="footnote-ref" href="#fn:677" rel="footnote">16</a></sup>  <sup id="fnref:678"><a class="footnote-ref" href="#fn:678" rel="footnote">17</a></sup>. In randomized clinical trials, recommended metronidazole regimens have resulted in cure rates of approximately 84%–98% <sup id="fnref:679"><a class="footnote-ref" href="#fn:679" rel="footnote">18</a></sup>  <sup id="fnref:680"><a class="footnote-ref" href="#fn:680" rel="footnote">19</a></sup>  <sup id="fnref:681"><a class="footnote-ref" href="#fn:681" rel="footnote">20</a></sup>, and the recommended tinidazole regimen has resulted in cure rates of approximately 92%–100% <sup id="fnref:680"><a class="footnote-ref" href="#fn:680" rel="footnote">19</a></sup>  <sup id="fnref:682"><a class="footnote-ref" href="#fn:682" rel="footnote">21</a></sup>  <sup id="fnref:683"><a class="footnote-ref" href="#fn:683" rel="footnote">22</a></sup>  <sup id="fnref:684"><a class="footnote-ref" href="#fn:684" rel="footnote">23</a></sup>  <sup id="fnref:685"><a class="footnote-ref" href="#fn:685" rel="footnote">24</a></sup>. Randomized controlled trials comparing single 2 g doses of metronidazole and tinidazole suggest that tinidazole is equivalent or superior to metronidazole in achieving parasitologic cure and resolution of symptoms <sup id="fnref:686"><a class="footnote-ref" href="#fn:686" rel="footnote">25</a></sup>.</p>
<p>Metronidazole gel does not reach therapeutic levels in the urethra and pervaginal glands. Because it is less efficacious than oral metronidazole, it is not recommended.</p>
<div class="footnote">
<hr />
<ol>
<li id="fn:663">
<p>Hollman D, Coupey SM, Fox AS, et al. Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs. J Pediatr Adolesc Gynecol 2010;23:312–6.&#160;<a class="footnote-backref" href="#fnref:663" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
<li id="fn:664">
<p>Roth AM, Williams JA, Ly R, et al. Changing sexually transmitted infection screening protocol will result in improved case finding for Trichomonas vaginalis among high-risk female populations. Sex Transm Dis 2011;38:398–400.&#160;<a class="footnote-backref" href="#fnref:664" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a></p>
</li>
<li id="fn:665">
<p>Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011;49:4106–11.&#160;<a class="footnote-backref" href="#fnref:665" rev="footnote" title="Jump back to footnote 3 in the text">&#8617;</a></p>
</li>
<li id="fn:666">
<p>Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007;45:194–8.&#160;<a class="footnote-backref" href="#fnref:666" rev="footnote" title="Jump back to footnote 4 in the text">&#8617;</a></p>
</li>
<li id="fn:667">
<p>Dize L, Agreda P, Quinn N, et al. Comparison of self-obtained penile-meatal swabs to urine for the detection of C. trachomatis, N. gonorrhoeae and T. vaginalis. Sex Transm Infect 2013;89:305–7.&#160;<a class="footnote-backref" href="#fnref:667" rev="footnote" title="Jump back to footnote 5 in the text">&#8617;</a></p>
</li>
<li id="fn:668">
<p>Campbell L, Woods V, Lloyd T, et al. Evaluation of the OSOM Trichomonas rapid test versus wet preparation examination for detection of Trichomonas vaginalis vaginitis in specimens from women with a low prevalence of infection. J Clin Microbiol 2008;46:3467–9.&#160;<a class="footnote-backref" href="#fnref:668" rev="footnote" title="Jump back to footnote 6 in the text">&#8617;</a></p>
</li>
<li id="fn:669">
<p>Huppert JS, Hesse E, Kim G, et al. Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians. Sex Transm Infect 2010;86:514–9.&#160;<a class="footnote-backref" href="#fnref:669" rev="footnote" title="Jump back to footnote 7 in the text">&#8617;</a></p>
</li>
<li id="fn:670">
<p>Andrea SB, Chapin KC. Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol 2011;49:866–9.&#160;<a class="footnote-backref" href="#fnref:670" rev="footnote" title="Jump back to footnote 8 in the text">&#8617;</a></p>
</li>
<li id="fn:671">
<p>Brown HL, Fuller DD, Jasper LT, et al. Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol 2004;12:17–21.&#160;<a class="footnote-backref" href="#fnref:671" rev="footnote" title="Jump back to footnote 9 in the text">&#8617;</a></p>
</li>
<li id="fn:475">
<p>Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009;200:e181–7.&#160;<a class="footnote-backref" href="#fnref:475" rev="footnote" title="Jump back to footnote 10 in the text">&#8617;</a></p>
</li>
<li id="fn:672">
<p>Mohamed OA, Cohen CR, Kungu D, et al. Urine proves a poor specimen for culture of Trichomonas vaginalis in women. Sex Transm Infect 2001;77:78–9.&#160;<a class="footnote-backref" href="#fnref:672" rev="footnote" title="Jump back to footnote 11 in the text">&#8617;</a></p>
</li>
<li id="fn:673">
<p>Lawing LF, Hedges SR, Schwebke JR. Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 2000;38:3585–8.&#160;<a class="footnote-backref" href="#fnref:673" rev="footnote" title="Jump back to footnote 12 in the text">&#8617;</a></p>
</li>
<li id="fn:674">
<p>Stoner KA, Rabe LK, Meyn LA, et al. Survival of Trichomonas vaginalis in wet preparation and on wet mount. Sex Transm Infect 2013;89:485–8.&#160;<a class="footnote-backref" href="#fnref:674" rev="footnote" title="Jump back to footnote 13 in the text">&#8617;</a></p>
</li>
<li id="fn:675">
<p>Kingston MA, Bansal D, Carlin EM. 'Shelf life' of Trichomonas vaginalis. International journal of STD and AIDS 2003;14:28–9.&#160;<a class="footnote-backref" href="#fnref:675" rev="footnote" title="Jump back to footnote 14 in the text">&#8617;</a></p>
</li>
<li id="fn:676">
<p>Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis 1975;51:51–3.&#160;<a class="footnote-backref" href="#fnref:676" rev="footnote" title="Jump back to footnote 15 in the text">&#8617;</a></p>
</li>
<li id="fn:677">
<p>Viitanen J, Haataja H, Mannisto PT. Concentrations of metronidazole and tinidazole in male genital tissues. Antimicrob Agents Chemother 1985;28:812–4.&#160;<a class="footnote-backref" href="#fnref:677" rev="footnote" title="Jump back to footnote 16 in the text">&#8617;</a></p>
</li>
<li id="fn:678">
<p>Mannisto P, Karhunen M, Mattila J, et al. Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration. Infection 1984;12:197–201.&#160;<a class="footnote-backref" href="#fnref:678" rev="footnote" title="Jump back to footnote 17 in the text">&#8617;</a></p>
</li>
<li id="fn:679">
<p>Spence MR, Harwell TS, Davies MC, et al. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol 1997;89(5 Pt 1):699–703.&#160;<a class="footnote-backref" href="#fnref:679" rev="footnote" title="Jump back to footnote 18 in the text">&#8617;</a></p>
</li>
<li id="fn:680">
<p>Gabriel G, Robertson E, Thin RN. Single dose treatment of trichomoniasis. J Int Med Res 1982;10:129–30.&#160;<a class="footnote-backref" href="#fnref:680" rev="footnote" title="Jump back to footnote 19 in the text">&#8617;</a></p>
</li>
<li id="fn:681">
<p>Thin RN, Symonds MA, Booker R, et al. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. Br J Vener Dis 1979;55:354–6.&#160;<a class="footnote-backref" href="#fnref:681" rev="footnote" title="Jump back to footnote 20 in the text">&#8617;</a></p>
</li>
<li id="fn:682">
<p>Prasertsawat PO, Jetsawangsri T. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 1992;19:295–7.&#160;<a class="footnote-backref" href="#fnref:682" rev="footnote" title="Jump back to footnote 21 in the text">&#8617;</a></p>
</li>
<li id="fn:683">
<p>Apte VV, Packard RS. Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis: report of a multicentre study. Drugs 1978;15(Suppl 1):43–8.&#160;<a class="footnote-backref" href="#fnref:683" rev="footnote" title="Jump back to footnote 22 in the text">&#8617;</a></p>
</li>
<li id="fn:684">
<p>Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res 1977;5:438–41.&#160;<a class="footnote-backref" href="#fnref:684" rev="footnote" title="Jump back to footnote 23 in the text">&#8617;</a></p>
</li>
<li id="fn:685">
<p>Mati JK, Wallace RJ. The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth. East Afr Med J 1974;51:883–8.&#160;<a class="footnote-backref" href="#fnref:685" rev="footnote" title="Jump back to footnote 24 in the text">&#8617;</a></p>
</li>
<li id="fn:686">
<p>Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;2:CD000218.&#160;<a class="footnote-backref" href="#fnref:686" rev="footnote" title="Jump back to footnote 25 in the text">&#8617;</a></p>
</li>
</ol>
</div>
        </div>
            </div>
        </div>
    </body>
</html>
        